Stockscreener 앱 받기
43.85
0.58%
0.165
전일 마감가:
$43.69
열려 있는:
$43.55
하루 거래량:
255.56K
Relative Volume:
0.53
시가총액:
$2.04B
수익:
$307.03M
순이익/손실:
$-99.81M
주가수익비율:
-21.19
EPS:
-2.0695
순현금흐름:
$-27.20M
1주 성능:
+6.38%
1개월 성능:
+4.55%
6개월 성능:
+7.92%
1년 성능:
+70.06%
1일 변동 폭
$43.18
$44.29
1주일 범위
$40.29
$44.34
52주 변동 폭
$23.83
$54.23
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
명칭
Mirum Pharmaceuticals Inc
전화
650-667-4085
주소
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
MIRM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
43.85 | 2.04B | 307.03M | -99.81M | -27.20M | -2.0695 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.10 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
606.65 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
655.59 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.05 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.08 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-04-17 | 개시 | Stifel | Buy |
| 2023-12-18 | 재확인 | H.C. Wainwright | Buy |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-11-13 | 개시 | Morgan Stanley | Overweight |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-17 | 재개 | Evercore ISI | Outperform |
| 2023-09-20 | 개시 | JMP Securities | Mkt Outperform |
| 2022-09-01 | 개시 | Citigroup | Buy |
| 2021-09-20 | 개시 | JP Morgan | Overweight |
| 2020-08-07 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | 개시 | H.C. Wainwright | Buy |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-06-25 | 개시 | Robert W. Baird | Outperform |
| 2019-08-12 | 개시 | Citigroup | Buy |
| 2019-08-12 | 개시 | Evercore ISI | Outperform |
| 2019-08-12 | 개시 | Guggenheim | Buy |
| 2019-08-12 | 개시 | ROTH Capital | Buy |
| 2019-08-12 | 개시 | Raymond James | Outperform |
모두보기
Mirum Pharmaceuticals Inc 주식(MIRM)의 최신 뉴스
Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities - Seeking Alpha
Learn to Evaluate (MIRM) using the Charts - news.stocktradersdaily.com
Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 - Business Wire
Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses - DutchNews.nl
Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last? - Yahoo Finance
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Acquired by Russell Investments Group Ltd. - Defense World
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $58.20 Consensus Target Price from Analysts - Defense World
Research Analysts Offer Predictions for MIRM Q1 Earnings - Defense World
Geode Capital Management LLC Grows Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM): Are Analysts Optimistic? - simplywall.st
FDA Approves Mirum Pharmaceuticals’ Drug For Rare Liver Disease Patients In Tablet Form: Retail Stays Bullish - NewsBreak: Local News & Alerts
Mirum gets FDA nod for tablet version of liver drug, Livmarli - MSN
Mirum stock in focus after FDA nod for Livmarli tablet (MIRM) - Seeking Alpha
Mirum Pharmaceuticals Says FDA Approves Tablet Formulation of Treatment for Cholestatic Pruritus - marketscreener.com
Mirum'S Livmarli Now FDA Approved In Tablet Formulation - marketscreener.com
Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation - Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Mirum Pharma Expands Team with Major Equity Awards Package for Key New Talent - Stock Titan
Vanguard Group Inc. Has $100.26 Million Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Mirum Pharmaceuticals Inc [MIRM] stock was sold by Howe Jolanda at the price of US$0.11 million - knoxdaily.com
KLP Kapitalforvaltning AS Makes New $277,000 Investment in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by Corebridge Financial Inc. - Defense World
Alagille Syndrome Market Growth to Accelerate in Forecast - openPR.com
(MIRM) Investment Report - news.stocktradersdaily.com
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Purchased by Teacher Retirement System of Texas - Defense World
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
Mirum Pharmaceuticals (MIRM) Down 1.9% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
MIRM Stock Sees Decline of Approximately -3.74% in Last Five Days - knoxdaily.com
Mirum Pharmaceuticals Says Livmarli Approved in Japan for Pruritus - MarketScreener
LIVMARLI Now Approved In Japan For ALGS And PFIC - MarketScreener
LIVMARLI Now Approved in Japan for ALGS and PFIC - Business Wire
First-Ever Treatment for ALGS and PFIC Approved in Japan: LIVMARLI Makes History - Stock Titan
Mirum Pharmaceuticals: Set Fair For Share Price MomentumReversing My Sell Call (MIRM) - Seeking Alpha
Maintaining An 'Accumulate' Rating On Mirum Pharmaceuticals, Lots To Like (NASDAQ:MIRM) - Seeking Alpha
Exploring 3 High Growth Tech Stocks in the US Market - simplywall.st
Charles Schwab Investment Management Inc. Purchases 4,478 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
(MIRM) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe - Nasdaq
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Looks Inexpensive But Perhaps Not Attractive Enough - simplywall.st
Mirum Pharmaceuticals SVP Jolanda Howe sells $107,342 in stock By Investing.com - Investing.com Australia
Mirum’s Rare Disease Strategy: A Blueprint For Sustainable Growth - insights.citeline.com
Mirum Pharmaceuticals SVP Jolanda Howe sells $107,342 in stock - Investing.com India
Mirum Pharmaceuticals CEO sells $1.2 million in stock By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals president sells $348k in stock - Investing.com India
Mirum Pharmaceuticals CEO sells $1.2 million in stock - Investing.com
Mirum Pharmaceuticals’ SVP Jolanda Howe sells $2.4 million in stock By Investing.com - Investing.com UK
Mirum Pharmaceuticals director Heron buys $24,214 in stock By Investing.com - Investing.com Australia
Mirum Pharmaceuticals director Heron buys $24,214 in stock - Investing.com India
Mirum Pharmaceuticals Inc (MIRM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.35%
0.36%
자본화:
|
볼륨(24시간):